List view / Grid view
Alltrna is redefining the future of rare disease treatment with engineered tRNA therapeutics that target genetic mutations - not just individual diseases. CEO Michelle Werner shares how this bold, mutation-driven approach could unlock universal treatments for thousands of patients long overlooked by traditional medicine.
Preclinical and clinical development are critical to the success of ADCs, where early strategic decisions regarding manufacturability and scalability can make or break a project. Iwan Bertholjotti of Lonza emphasises the importance of proactive planning to avoid costly delays and ensure smooth progress towards clinical success.
Advancements in chronic lymphocytic leukaemia (CLL) treatment, like the AMPLIFY Phase III trial combining acalabrutinib and venetoclax, offer less toxic and more effective options. Learn from AstraZeneca’s Benjamin Moutier about how this breakthrough highlights the potential of targeted therapies to improve outcomes and reduce treatment burden, marking a key moment…
Vitalant is transforming the path from preclinical drug discovery to patient care by enabling access to cutting-edge cell and gene therapies. With decades of expertise and a nationwide network, find out how they bridge the gap between innovative treatments and local communities, ensuring life-changing therapies reach patients efficiently.
Scenic Biotech and Stanford University have published a study identifying PLA2G15 as a new drug target in neurodegenerative and metabolic diseases, potentially enabling future treatments for conditions like Niemann-Pick type C.
The partnership allows for the further development of AI-designed RNA-targeted therapies for a range of diseases.
Outdated clinical development systems are slowing breakthroughs like gene therapies and precision medicine. This article explores how a flexible, on-demand approach can accelerate drug development and bring innovations to patients faster.
Discover how Chromatin Bioscience’s synthetic promoters are transforming gene therapy by enhancing precision, boosting safety and improving manufacturing efficiency.
Tubulis, led by CEO Dominik Schumacher, is advancing cancer treatment through next-generation antibody-drug conjugates (ADCs) designed to target solid tumours more effectively. Find out how the company is rapidly progressing its ADC pipeline to offer more precise and lasting treatment options for patients.
Abelacimab represents a breakthrough in drug discovery, offering a novel approach to anticoagulation that could potentially prevent strokes with minimal bleeding risk. Learn how this innovative treatment could set new standards for both clinical practice and pharmaceutical research.
Discover how a leader in CMC regulatory affairs is transforming drug development and inspiring the next generation of scientists.
A new publication in Nature Medicine highlights the potential of VE303 for preventing recurrent C. difficile infection, detailing its impact on the gut microbiome and immune response.
Bio-Rad has launched Nuvia wPrime 2A Media, a scalable resin designed for biomolecule purification in research and biotherapeutic applications.
Regulatory changes are reshaping toxicology, with precision now at the forefront. We explore how accurate target analysis is transforming drug development, particularly for biotherapeutics.
A new blood-brain barrier-crossing platform enables the delivery of therapeutic molecules to the brain, offering potential treatments for ALS and Alzheimer’s disease.
